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Abstract 
Background 
Resistance to endocrine therapy remains a major clinical problem in the treatment of estrogen-
receptor positive (ER+) breast cancer. Studies show androgen-receptor (AR) remains present 
in 80-90% of metastatic breast cancers providing support for blockade of AR-signalling. 
However, clinical studies with abiraterone, which blocks cytochrome P450 17A1 (CYP17A1) 
showed limited benefit.  
Methods 
In order to address this, we assessed the impact of abiraterone on cell-viability, cell-death, ER-
mediated transactivation and recruitment to target promoters together with ligand-binding 
assays in a panel of ER+ breast cancer cell lines that were either estrogen-dependent, modelling 
endocrine-sensitive disease, or estrogen-independent modelling relapse on an aromatase 
inhibitor. The latter, harboured wild-type (wt) or naturally occurring ESR1 mutations  
Results 
Similar to estrogen, abiraterone showed paradoxical impact on proliferation by stimulating cell 
growth or death, depending on whether the cells are hormone-dependent or have undergone 
prolonged estrogen-deprivation, respectively. Abiraterone increased ER-turnover, induced ER-
mediated transactivation and ER-degradation via the proteasome.  
Conclusion 
Our study confirms the estrogenic activity of abiraterone and highlights its differential impact 
on cells dependent on estrogen for their proliferation versus those that are ligand-independent 
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and harbour wt or mutant ESR1. These properties could impact the clinical efficacy of 
abiraterone in breast cancer. 
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Introduction 
Endocrine therapies have been very successful in treating estrogen receptor-positive (ER+) 
breast cancer, which accounts for over 70% of all breast cancers. However, almost 40% of 
patients relapse on therapy 1-6. Identification of potential resistance mechanisms associated with 
either de novo or acquired resistance is therefore of paramount clinical importance. 
Unfortunately, cancer is a very heterogeneous disease 7-11 and depending on the patient and the 
cancer genetic/epigenetic landscape, multiple resistance mechanisms can occur (reviewed by 
4), suggesting that one drug cannot fit all. 
The androgen receptor (AR) is expressed in 50-70% of all breast cancer. In particular 80-90% 
of ER+ breast cancer also express AR which associates with a more favourable prognosis 12,13. 
Nonetheless, pre-clinical studies indicate increased abundance of AR reduces response to both 
tamoxifen and estrogen-deprivation 14,15 an observation that has been supported in retrospective 
clinical investigations 14,16. Furthermore, pre-clinical studies have suggested the potential 
usefulness of therapies that target AR signalling in breast cancer 16 and have paved the way for 
a number of clinical trials 17,18,19.  
Several drugs are used to block AR action: enzalutamide and bicalutamide that function as AR-
antagonists, enobosarm that acts as a selective AR modulator (SARM) and abiraterone, a 
steroidal compound that blocks CYP17A1 19-21. 
However, clinical studies in breast cancer to date have shown mixed response to blockade of 
AR signalling. For instance, enobosarm provided clinical benefit in 6/17 ER+ metastatic breast 
cancer patients 22, while abiraterone showed no improvement in progression-free survival (PFS) 
in a similar cohort 18.  
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A recent in-vitro study showed abiraterone acted as an agonist in ER+ breast cancer cells and 
elicited ER-transcriptional activity 23. Such estrogenic activity could impact on the 
effectiveness of abiraterone in the clinic given the proliferative response to estrogen signalling 
by most ER+ breast cancer. However, the cell line model used by Capper et al 23 was 
representative of the endocrine therapy naïve setting and therefore did not recapitulate the 
clinical scenario in which the drug is currently being tested. In order to address the potential 
mechanism underlying the lack of clinical benefit gained from abiraterone in ER+ metastatic 
breast cancer patients, we investigated its impact on ER-signalling in a panel of ER+ breast 
cancer cell lines sensitive (i.e dependent on estrogen for their proliferation) or resistant to long-
term estrogen-deprivation (LTED), modelling relapse on an aromatase inhibitor (AI), and 
harbouring various naturally occurring ESR1 mutations. Our data indicate that abiraterone may 
have context-dependent roles in ER+ breast cancer that can be influenced by prior hormonal 
therapies and that ESR1 mutation status may influence its efficacy in the clinical setting. 
 
Materials and Methods 
Cell culture 
All wild type (wt) cell lines (MCF7, HCC1428 and SUM44) were purchased from ATCC or 
Asterand. Upon receipt cells were aliquoted to prevent phenotypic drift and authenticated by 
STR. All cell lines were routinely screened for mycoplasma infection. The wt cell lines were 
cultured in phenol red-free RPMI 1640 (Gibco, Thermo Fisher Scientific, UK) supplemented 
with 10% FBS (Gibco, Thermo Fisher Scientific, UK) and 1nM 17-b-estradiol (E2) (Sigma-
Aldrich, UK). Long-term estrogen deprived (LTED) derivatives of the cell lines were cultured 
in phenol red-free RPMI 1640 in the absence of exogenous E2 and supplemented with 10% 
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dextran charcoal-stripped bovine serum (referred to as 10% DCC medium) 24. Two MCF7-
LTED derivatives were used within the study one harbouring wt-ESR1 (MCF7-LTEDwt), the 
other harbouring a naturally occurring ESR1Y537C mutation (MCF7-LTEDY537C). Additionally 
SUM44-LTED express an ESR1Y537S mutation (SUM44-LTEDY537S) whilst HCC1428-LTED 
contain wt-ESR1 25. 
 
Proliferation assays 
Wt cell lines were stripped of E2 by culturing in 10% DCC medium for 5 days, with daily 
medium changes. LTED and stripped wt cell lines were seeded into 96-well tissue culture plates 
(Greiner one, UK) in 10% DCC medium, as previously described 26. Cells were allowed to 
acclimatize overnight. Monolayers were treated with escalating concentrations of abiraterone 
(CAS no-S1123, SelleckChem, UK), E2, ICI (ICI 182,780) (CAS no 129453-61-8, 
SelleckChem, UK) or combinations of the agents over a 6-day period. Treatment medium was 
replenished on day 3. Cell viability was determined using CellTitre-Glo® Luminescent Cell 
Viability Assay (Promega), according to the manufacture’s protocol. Luminescent signal was 
read on Victor spectrophotometer (Perkin Elmer, Wokingham, UK). Values were expressed as 
percent (%) viable cells relative to the vehicle treated control. Statistical analysis was 
performed in Prism using non-linear fit curve, two-way ANOVA and multiple comparison 
analysis using Dunnett’s test. For the siRNA knockdown assays, cells were seeded in 10% 
DCC and transfected with sicontrol (non-targeting pool) or siRNA targeting ESR1 or AR (ON-
TARGETplus siRNA, GE Dharmacon) using lipofectamine RNAimax (Invitrogen, Grand 
Island, NY, USA) 26, according to the manufacturer’s protocol. After 24 hours, monolayers 
were then treated with 10% DCC plus or minus estrogen (1nM) or abiraterone (7.5μM) and 
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cells cultured for a total of 6 days. The efficiency of the knock down was assessed by qRTPCR. 
Cell viability was determined using the CellTitre-Glo® Luminescent Cell Viability Assay 
(Promega). Values were expressed as fold-change relative to the vehicle treated control. 
Statistical analysis was performed using Student’s t-test. 
 
Live cell imaging 
In order to monitor proliferation over time live cell imaging was conducted using Incucyte S3 
Live-Cell Analysis System (Essen Bioscience). In brief, cells were stripped of E2 as described 
above and seeded into 96-well tissue culture plates. Drugs were administered and phase-
contrast images of the wells were acquired every 4 hours in real time over 7 days. Masks were 
created using Incucyte S3 software to quantitate percentage phase-contrast confluence for each 
well and quantified time-lapse curves were generated. Data represent mean of 6-8 replicates 
(16 images per time point). Statistical analysis was performed in Prism using 2-way ANOVA. 
 
Proliferation assay in spheroids 
HCC1428-LTED spheroids, were generated by seeding 2000 cells in 10% DCC medium, into 
ultralow attachment 96-well plates (Corning, UK) and centrifuged for 10 minutes at 900rpm. 
After 3 days, spheres were treated with escalating doses of abiraterone and re-treated every 3-
4 days. After 10 days of treatment images of spheres were taken using CeligoS (Nexcelome 
Bioscience, Lawrence, MA, US) and viability was assessed using CellTitre-Glo® Luminescent 
3D Cell Viability Assay (Promega, UK). 
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Transcription assays 
Stripped wt cells and LTED cells were seeded into 24-well plates 27 in 10% DCC medium. The 
following day, the cells were transfected with an estrogen response element linked luciferase 
(EREtkLuc) and β-galactosidase reporter-constructs using Fugene® 6 (Promega) 27. The 
following day, cells were treated for the respective treatments highlighted within the figure 
legends for 24 hours. The luciferase activity (Promega) and β-galactosidase (GalactoStar; 
Applied Biosystems) were measured using a luminometer. Each experiment was performed in 
triplicate and the luciferase values were normalized to the β-galactosidase. For the proteasome 
inhibition experiments, the cells were treated for 16 hours as previously described 28. Statistical 
analysis was performed using Student’s t-test. 
 
Ligand binding assays 
Stripped wt-MCF7 and MCF7-LTEDY537C cells were seeded into 12 well plates at a density of 
2.5x104 cells per well in 10% DCC medium and allowed to acclimatise for 24 hours. The 
following day, cells were transferred to serum free medium for a further 24 hours.  
Subsequently, cells were treated in competition assays with 2nM 3H-E2 29 and escalating 
concentrations of E2 or abiraterone.  Monolayers were incubated for 2 hours at 37oC, washed 
twice with cold phosphate buffered saline (PBS) and lysed in 250µl of protein lysis buffer. 
Radioactivity was measured (1900CA analyser, Perkin Elmer) 30. Experiments were conducted 
in triplicate. Prism was used to calculate Ki and IC50 using non-linear regression analysis. 
Western blot  
Protein extracts were generated, as previously described 31.  Equal amounts of protein were 
resolved by SDS-PAGE and subjected to immunoblot analysis. Antigen-antibody interactions 
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were detected with ECL-reagent (Amersham, Amersham, UK). Proteins were detected using 
the following antibodies: total-ESR1 (Santa-Cruz sc8002), PGR (Novocastra NCL-L-PGR), 
TFF1 (ab92377), GREB1 (ab72999), AR (CST-5153), CCND3 (CST-2936), CDK4 (CST-
2906), pRBser780 (CST-3590), pRBser807 (CST-9308), p130 (sc-317), p107 (sc-318), total-
RB (CST-9309), and tubulin (Sigma T-9026). Secondary antibodies were used at concentration 
of 1/2000 (Dako, Denmark A/S). MG-132 was purchased from Selleckchem (S2619) and was 
used at 10μM final concentration. 
 
Tandem ubiquitin-binding entity (TUBE) 
Cells were lysed on ice in lysis buffer [200 mM Tris HCL pH 7.5, 150 mM NaCl, 2 mM EDTA, 
10% Glycerol, 50 mM NaF, 200 μM NaVO4, complete protease inhibitor cocktail EDTA-free 
from Roche, supplemented with fresh PR619 (DUB inhibitor, 1:2000, SI9619 LifeSensors). 
Supernatant was collected after 10 minutes centrifugation in a cooling centrifuge. Protein lysate 
was incubated together with pre-washed glutathione sepharose beads (GST Sepharose 4B, GE 
Healthcare) and recombinant ubiquitin in a rocker overnight at 4oC. The next day, the samples 
were washed five times with washing buffer (PBS, 1% Triton, 1 mM EDTA plus PR619) and 
centrifuged each time at 4000 rpm for 30 sec at 4oC. After complete removal of the last wash 
by aspiration, samples were boiled using laemmli (plus DTT) and subjected to SDS-PAGE and 
western blot analysis. Primary antibodies used were; ER (Santa-Cruz sc8002) and ubiquitin 
(P4D1, CST-3936). Secondary antibodies were used at concentration of 1/2000 (Dako, 
Denmark A/S). 
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qRT-PCR  
RNA was extracted 24 hours after treatments using RNeasy columns and quantification was 
performed using a NanoDrop 1000 spectrometer. cDNA was generated using SuperScript III 
First Strand Synthesis System for RT-PCR (Invitrogen, Grand Island, NY, USA). cDNA was 
subjected to quantitative PCR (Applied Biosystems). Taqman gene expression assays (Applied 
Biosystems) was used ESR1 (Hs00907239_m1), AR (Hs00171172_m1) and FKBP15 
(Hs00391480_m1) as housekeeping gene, to normalise the data. The relative quantity was 
determined using ΔΔCt. 
 
ChIP qPCR 
ChIP experiments were performed, as previously described 32. Briefly, cells were synchronized 
with a-amanitin 33, then treated for 45 minutes with E2 (1nM), ICI (10nM), abiraterone 
(7.5µM) or combination and fixed. The antibodies used were anti-ER (Santa Cruz 
Biotechnology; sc-543 X), anti-CBP (Santa Cruz Biotechnology; sc-369 X) and Mouse IgG1 
(Dako, Denmark A/S). The resulting DNA was subjected to quantitative PCR analysis using 
SYBR green (Applied Biosystems) with the following primers for TFF1: (forward) 5’ - GGC 
CAT CTC TCA CTA TGA ATC ACT TCT GCA - 3’ and (reverse) 5’ - GGC AGG CTC TGT 
TTG CTT AAA GAG CGT TAG - 3’, and for GREB1: (forward) 5’- GAA GGG CAG AGC 
TGA TAA CG 3’ and (reverse) 5’- GAC CCA GTT GCC ACA CTT TT. 
Cell death assay 
Cell death assays were carried out as previously described 34. In brief, cells were seeded in 96 
well plates and 24 hours later were treated with increasing doses of abiraterone or E2. The 
treatment was replaced after 3 days and cells were cultured for a total of 6 days. PI was added 
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after 6 days. Cell death was analyzed by flow cytometry quantification of PI (2 μg/mL) uptake 
using a FACSCalibur (BD Biosciences). Statistical analysis was performed using one-way 
ANOVA with Bonferroni correction. 
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Results 
The differential impact of abiraterone on the proliferation of cell lines resistant to LTED 
Given the recent findings suggesting abiraterone can induce growth in ER+ breast cancer cells 
in vitro 23, we assessed the impact of abiraterone on the proliferation of a panel of cell lines 
modelling both estrogen-dependent and independent growth (Figure 1) 31. Wt cell lines were 
grown in the absence of E2 for five days prior to the treatment with escalating concentrations 
of abiraterone. In order to be consistent with the abiraterone  concentrations used in previous 
studies, we adopted a concentration range of abiraterone  from 0.1-10μM 23,30.  
In keeping with previous findings 23, all wt ER+ breast cancer cell lines tested showed a 
concentration-dependent increase in proliferation in response to abiraterone  (wt-MCF7 EC50 
2.76µM (95% CI 2.60-2.94µM); wt-SUM44 EC50 1.56µM (95% CI 1.4-1.72µM); wt HCC1428 
EC50 2.06µM (95% CI 1.81-2.32µM)) (Figure 1A). Contrastingly, two MCF7-LTED models 
harbouring either ESR1wt or ESR1Y537C as well as HCC1428-LTED showed over a 50% 
reduction in proliferation in the same concentration range tested (MCF7-LTEDY537C IC50 
5.79µM (95% CI 5.41-6.18µM); MCF7-LTEDwt IC50 3.83µM (95% CI 3.54-4.13µM and 
HCC1428-LTED IC50 1.98 µM (95% CI 1.75-2.22µM)) (Figure 1B). However, SUM44-
LTEDY537S cells were resistant to the anti-proliferative effect of abiraterone (Figure 1C).  
The contrasting effect of abiraterone was confirmed in MCF7 isogenic models using real-time 
imaging of cell growth over a period of 7 days (Figure 1D). Furthermore, the antiproliferative 
effect of abiraterone within the LTED cells was confirmed in 3D spheroids (Supplementary 
Figure S1).  
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As abiraterone is known to have a steroidal structure 21, we hypothesised the drug may directly 
bind to ER. In order to address this, we conducted competitive ligand binding assays. The Ki 
for wt-MCF7 in response to E2 was 0.16nM (95% CI 0-1.58) and for MCF7-LTEDY537C 
0.27nM (95% CI 0.09-0.6). Binding of abiraterone demonstrated a Ki of 0.39µM (95% CI 0.1-
1.2) for wt-MCF7 and 0.25µM (95% CI 0-3.6) for MCF7-LTEDY537C (Supplementary Table 
S1).  
To assess the apparent context-specific agonist and antagonist nature of abiraterone, wt-MCF7 
and MCF7-LTED cell line models were treated with three concentrations of E2 (0.001, 0.01 
and 0.1 nΜ), escalating concentrations of abiraterone alone or in combination (Figure 2A-C). 
The agonist activity of abiraterone in wt-MCF7 was decreased by the addition of E2 in a dose-
dependent manner (Figure 2A) (adj. p<0.0001 Dunnett’s test). Contrastingly, abiraterone alone 
caused a concentration-dependent decrease in the cell viability of MCF7-LTEDwt and MCF7-
LTEDY537C, which was enhanced by the addition of E2 (adj. p<0.0001, Dunnett’s test) (Figure 
2B and C).  
To explore the estrogenic activity of abiraterone, wt-MCF7 and MCF7-LTEDY537C were treated 
with ICI, a drug that degrades ER, in the presence or absence of abiraterone. As expected, the 
wt-MCF7, in the absence of ligand, a setting in which ER is not cycling on promoters, showed 
no response to escalating concentrations of ICI, however, addition of abiraterone resulted in a 
marked decrease in proliferation (IC50= 0.45nM) (Figure 2D). In contrast MCF7-
LTEDY537C,which are estrogen-independent showed a dose-dependent decrease in proliferation 
in response to ICI alone (IC50=0.23nM) supporting their ligand-independent phenotype. 
Addition of abiraterone shifted the dose response curve to the right (IC50=1.3nM) suggesting 
abiraterone antagonised the anti-proliferative effect of ICI (Figure 2E).  
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Taken together, these data suggest that the weak estrogenic activity of abiraterone, potentially 
given its steroidal structure, may impact on ER-signalling, in a context-specific manner 
depending on the history of the cells and the ESR1 mutation status. 
ER-activity is increased in the presence of abiraterone in both hormone-dependent and 
hormone-independent cell lines 
To address the impact of abiraterone on ER-mediated transactivation, in the MCF7-LTED 
models, cells were transfected with an estrogen-response-element (ERE) linked-luciferase 
reporter and exposed to escalating concentrations of abiraterone. ER-mediated transactivation 
was increased in a concentration-dependent manner, while ER-protein levels were decreased 
(Supplementary Figure S2A & B). We next assessed the relative effect of abiraterone and E2 
on ER-transactivation in the MCF7 isogenic models (Figure 3A). As expected, E2 caused a 
dramatic rise in ERE-linked luciferase activity, which was suppressed by the addition of ICI. 
Abiraterone also increased ER-mediated transcription 2-fold in wt-MCF7, 9-fold in the MCF7-
LTEDwt and 4-fold in MCF7-LTEDY537C (Figure 3A). Of note, the combination of abiraterone 
and E2 appeared to antagonise E2-mediated transcription although this did not meet statistical 
significance (p>0.1). The effect of single agent abiraterone was antagonised by the addition of 
ICI in all cell lines tested, causing a greater than 4-fold reduction in ER-activity (p<0.005). 
These data were confirmed in HCC1428-LTED but not SUM44-LTED cells which harbour the 
ESR1Y537S mutation (Supplementary Figure S2C).  
 
The impact of abiraterone on ER was also assessed in a viability assay where ER was knocked 
down in wt-MCF7 in the absence of ligand or in the presence of E2 or abiraterone (Figure 3B 
and Supplementary Figure S3). In this setting, siER caused 74% drop in the viability of wt
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MCF7 in the presence of E2 (p<0.001) and 60% drop in the presence of abiraterone (p<0.001). 
As expected in the absence of ligand (DCC medium), a setting in which ER is no longer 
cycling, siER had no impact on viability. This result was not recapitulated when the AR was 
knocked down either in the wt-MCF7 or MCF7-LTEDY537C (Figure 3B and Supplementary 
Figure S3). This suggests that abiraterone, similar to E2, allows ER to cycle on promoters but 
does not impact on AR in these models. 
To further assess the impact of abiraterone on ER-transactivation, chromatin 
immunoprecipitation (ChIP) of ER and its co-activator CREB binding protein (CBP) were 
conducted in synchronized wt-MCF7, MCF7-LTEDwt and MCF7-LTEDY537C in response to 
abiraterone or abiraterone plus ICI. Recruitment of ER and CBP was enriched in response to 
abiraterone on both TFF1 and GREB1 promoters (Figure 3C) and a concordant increase in 
protein abundance was observed for TFF1 and GREB1 in all MCF7 cell lines tested. PGR 
increased significantly in wt-MCF7 cells in response to abiraterone and to a lesser degree in 
MCF7-LTEDY537C. As expected, MCF7-LTEDwt cells, which express very low levels of PGR, 
showed the least response to abiraterone. Noteworthy, no impact on AR was evident (Figure 
3D). In further support, addition of ICI caused a reduction in ER and CBP recruitment (Figure 
3C).  
In summary, these data provide further support suggesting abiraterone can bind the ER 
complex and enhance its activity. 
Abiraterone-induced ERα-transactivation is dependent on classical proteasome-
mediated degradation  
The transcriptional activity of ER is dependent on proteasome function leading to the cyclical 
binding of ER on ERE within target genes 28,35. Since abiraterone appeared to enhance ER-
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mediated transcription, we assessed its impact on ER-proteasomal degradation. Addition of the 
proteasome inhibitor MG-132 caused a 50% reduction in E2 (p=0.0002) and a 70% decrease 
in abiraterone ER-mediated transactivation (p<0.00001) (Figure 4A and B). As ER levels drop 
in response to ligand binding, we conducted tandem ubiquitin binding entity (TUBE) 36, in 
order to confirm the association of ER with ubiquitin in response to ligand. Cell lines were 
treated with E2, abiraterone alone or in combination with MG-132. As expected, capture of 
ubiquitylated proteins showed enrichment in response to MG-132 (Figure 4C). 
Immunoblotting for un-modified ER showed enrichment with abiraterone or E2 in combination 
with MG-132 (Figure 4C). Furthermore, addition of MG-132 also reduced the abundance of 
TFF1 (Figure 4D). Taken together, these data suggest the ability of abiraterone to promote ER-
activity via ligand-dependent proteasome-mediated cycling. 
Abiraterone showed alternate effects on cell cycle in wt-MCF7 and LTED model systems 
As abiraterone appeared to have differential effects on cell proliferation in the wt-MCF7 and 
MCF7-LTED models, we assessed its impact on cell cycle markers of the G1/S phase after 48 
hours treatment with abiraterone. In wt-MCF7 cells, previously stripped of E2, abiraterone 
treatment increased abundance of CCND3, CDK4, pRB and p107 indicative of cell cycle 
progression. Contrastingly, no impact was evident on these cell cycle regulatory proteins in the 
MCF7-LTED cells after 48 hours. To address this further we carried out a time course over 96 
hours. Abiraterone appeared to have little impact on cell cycle over the first 24-48 hours. 
However, at 72 hours post treatment a reduction in CCND3, total RB and pRB was evident. 
(Figure 5A & B).  
Previously, we and others 37-41 have shown that high concentrations of E2, which elicit 
maximum proliferation of the wt-ER+ cell lines, produce an anti-proliferative effect in some 
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ER+ LTED models, an observation that we recapitulated in this study (Supplementary Figure 
S4). Contrastingly SUM44-LTED, which harbour an ESR1Y537S mutation, showed no response 
to either abiraterone  (Figure 1C) or E2 (Supplementary Figure S4). 
We hypothesised that abiraterone may have a similar impact. We therefore treated wt-MCF7 
and both MCF7-LTED models with escalating concentrations of abiraterone for 6 days and 
determined cell death using propidium iodide exclusion. As expected, abiraterone caused a 
concentration-dependent increase in cell death in the MCF7-LTED. This observation was 
confirmed in a second model, HCC1428-LTED (Figure 5C). 
These findings suggest that abiraterone exerts stimulatory or inhibitory effects in ER+ breast 
cancer, depending on whether the cells are estrogen-dependent (AI-sensitive) or estrogen-
independent (AI-resistant) but also that context in which resistance occurs can influences 
response to abiraterone. 
 
Discussion 
Despite the great efficacy of endocrine agents in treating ER+ breast cancer patients, relapse 
and outgrowth of cancer cells occurs in many patients with primary disease and invariably in 
metastatic disease 42. Therefore, identification of new treatment options is of paramount 
importance. Previous studies in prostate cancer have shown that abiraterone targets not only 
steroidogenesis but also directly antagonises AR activity 30. As 80% of ER+ breast cancer 
patients also express AR 12,13, we explored the notion that blocking AR signalling with 
abiraterone may provide benefit in ER+ breast cancer. Here, we provide mechanistic insights 
for the mode of action of abiraterone in ER+ breast cancer cell lines, modelling AI-sensitivity 
and resistant disease.  
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Our study revealed that abiraterone within the clinically achievable concentration range 43,44, 
had weak estrogenic activity but contrasting effects on proliferation in endocrine sensitive 
versus resistant breast cancer cell lines. More specifically, models of endocrine sensitive ER+ 
breast cancer showed increased proliferation and associated expression of G1/S checkpoint 
proteins indicative of cell cycle progression in response to abiraterone, whereas the reverse was 
true in the majority of cell lines modelling resistance to AI-therapy. This observation was 
independent of AR activity.  
ESR1 mutations are evident in approximately 20% of metastatic patients 45 and appear enriched 
in response to AI therapy. Indeed, a recent study showed 39.1% of patients treated with AI 
therapy harboured an ESR1 mutation in circulating tumour DNA and 49% of these were 
polyclonal 46,47. In order to explore the relevance of ESR1 mutations in response to abiraterone, 
we used a panel of LTED cell lines that harboured naturally occurring ESR1wt, ESR1Y537C or 
ESR1Y537S. Interestingly, SUM44-LTED, which express the ESR1Y537S were the least responsive 
to the anti-proliferative effects of abiraterone. In contrast, LTED cell lines expressing ESR1wt 
showed a marked reduction in proliferation with IC50 values over 30% lower than those seen 
for the ESR1Y537C mutant cell line. Concordantly, cell death in response to abiraterone was more 
pronounced in both MCF7-LTEDwt and HCC1428-LTED compared to MCF7-LTEDY537C. 
Previously, we and others have shown that LTED models retaining ligand-independent ER 
activity are sensitive to high concentrations of E2, which conversely support proliferation of 
wt-MCF7 cells 31,38-41,48 a phenomenon which has been exploited clinically 49. The present study 
suggests that abiraterone may cause cell death in a similar manner to E2, although this warrants 
further investigation.  
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To explore the estrogenic effect of abiraterone further, we assessed its impact on ER-mediated 
transactivation and ER-protein turnover. Abiraterone induced expression of estrogen-regulated 
genes TFF1, GREB1 and PGR, which was also reflected in the enhanced recruitment of ER 
and CBP to target promoters. Of note, abiraterone caused proteasomal degradation of ER 
similar to that seen with E2, suggesting its ability to act as a ligand promoting ER activity. 
Taken together, this suggests that an increase in the protein turnover of ER might re-initiate 
growth in estrogen-deprived MCF7 cells, whilst impacting negatively on the growth of MCF7-
LTED cells, potentially inducing apoptosis. 
Clinical studies exploring the inhibition of androgen production by abiraterone in patients who 
have relapsed on prior non-steroidal AI therapy have shown no added benefit compared to 
exemestane 18. In particular, there was no difference in the primary end point of PFS (50% PFS) 
between the abiraterone (3.7 months), exemestane (3.7 months) or the combination (4.5 
months). One explanation for the failure of the trial was the apparent increase in progesterone, 
which may have provided a mitogenic stimulus bypassing the requirement for CYP17 blockade 
17,18. Our data from the wt-MCF7, wt-HCC1428 and wt-SUM44 suggests that the combination 
of E2-deprivation and abiraterone treatment may enhance the agonist activity of abiraterone 
such that despite CYP17 blockade the drug itself can act as a ligand. Finally, the majority of 
patients within the trial received prior AI therapy and it is therefore likely that a large proportion 
harbour ESR1 mutations. Importantly, we showed LTED cells expressing ESR1Y537S a common 
hot-spot mutation were resistant to abiraterone, whilst LTED cells containing ESR1Y537C were 
responsive.  Previous studies have shown the Y537S mutation enables helix 12 to undergo a 
conformational change exposing the AF2 cleft thereby facilitating recruitment of co-regulators 
in the absence of E2 25,50. Furthermore, ligand-binding assays showed lower affinity for E2, 
tamoxifen and ICI compared to ESR1wt. 50. Hence we postulate abiraterone may not impact 
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either directly or indirectly on the ability of ESR1Y537S to drive proliferation. In the case of 
Y537C, it is unclear. It could hypothesised that as cysteine is a more reactive amino acid 51, it 
may impact on association of ESR1 with other proteins/cofactors and that binding of 
abiraterone may disrupt these interactions leading to cell death. Taken together, these data 
suggest the context in which resistance to AI-therapy is acquired may influence response to 
abiraterone highlighting once again the importance of correct patient selection.   
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Titles and legends to figures 
Figure 1. Alternate sensitivity to abiraterone in ER+ breast cancer cell line models. (A) Wt-
MCF7, wt-HCC1428, wt-SUM44 and (B) MCF7-LTEDwt, MCF7-LTEDY537C, HCC1428-
LTED and (C) SUM44-LTEDY537S cell lines were treated for 6 days with escalating 
concentrations of abiraterone (0.1-10μM). The concentration range used was based on previous 
published studies. Cell viability was measured using TitreGlo and expressed as percent viable 
cells compared to vehicle treated control. Wt lines were grown in hormone-deprived conditions 
for five days prior to treatment with abiraterone. (D) Time course analysis of proliferation in 
response to abiraterone (7µM) assessed using Incucyte over a period of 7 days with 4 hourly 
readings. Data is expressed as percentage of confluency. The data shown is representative of 
two independent biological experiments with six-eight replicates per treatment. Bars represent 
± SEM. 
Figure 2. Abiraterone exhibits estrogenic activity in wt-MCF7 and MCF7-LTED. Wt-
MCF7 cells were grown in hormone-deprived conditions prior to treatment. (A) Abiraterone 
(Abi) alone or in combination with three concentrations of E2 (0.001nM, 0.01nM, 0.1nΜ). (B) 
MCF7-LTEDwt or (C) MCF7-LTEDY537C were treated with escalating concentrations of 
abiraterone  (Abi) alone or in combination with three concentrations of E2. (D) Wt-MCF7 or 
(E) MCF7-LTEDY537C were treated with increasing doses of ICI 182,780 (ICI) alone, or with 
7.5μM Abi. Cell viability was measured using TitreGlo and expressed as fold change relative 
to vehicle treated control. Data shown is representative of two biological experiments and eight 
replicates per treatment. Bars represent ± SEM.  Statistical analysis was performed in Prism 
using two-way ANOVA and Dunnett’s test. 
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Figure 3. ER-mediated transactivation is increased in the presence of abiraterone and the 
action is reversed by ICI. (A) wt-MCF7, MCF7-LTEDwt or MCF7-LTEDY537C were 
transfected with an ERE-luciferase (EREII-tk-luc) reporter construct and treated with E2, 
abiraterone (Abi) , ICI 182,780 (ICI) alone or in combination. Data shown is representative of 
two biological experiments and three replicates per treatment. Bars represent ± SEM. (B) 
Viability assays on wt-MCF7 and MCF7-LTEDY537C in the presence of siRNA for control, ER 
and AR with or without abiraterone (Abi). (C) Chromatin immunoprecipitation (ChIP) of ER 
and its co-factor CBP was carried out in synchronized wt-MCF7, MCF7-LTEDwt and MCF7-
LTEDY537C. IgG was used as a negative control. The cells were synchronized with α-amanitin 
and treated for 45 minutes with Abiraterone (Abi), ICI 182,780 (ICI) or in combination. 
Recruitment of ER and CBP was assessed in the GREB1 and TFF1 promoters. Data shown is 
representative of three technical replicates. Bars represent ±SEM. (D) Protein levels of 
estrogen-regulated genes, GREB1, PGR and TFF1 together with ER and AR were assessed in 
the presence of abiraterone (Abi) (7.5 μM) for 48 hours in wt-MCF7, MCF7-LTEDwt and 
MCF7-LTEDY537C.  
 
Figure 4. Abiraterone, similarly to E2, facilitates ER-transactivation and ER-degradation 
via the proteasome. (A) wt-MCF7 (B) and MCF7-LTEDY537C were transfected with the EREII-
tk-luc construct and treated for 16 hours with E2, abiraterone, ICI or in combination in the 
presence or absence of MG-132 (10 μM). Data is representative of two biological experiments 
with three replicates for each treatment. Bars represent ± SEM. (C) Tandem ubiquitin-binding 
entity (TUBE) followed by immunoblot detection of ubiquitin and ER was carried out in wt-
MCF7 and MCF7-LTEDY537C, treated for 16 hours with E2 or abiraterone in the presence or 
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absence of MG-132 (10 μM). (D) Concomitant western blot analysis of ER and TFF1 assessed 
after 16 hours treatment with E2 or abiraterone in the presence or absence of MG-132 (10 μM). 
 
Figure 5. Abiraterone causes a drop in cell cycle markers and induces cell death. (A) The 
protein levels of cell cycle markers (CCND3, CDK4, pRB807, RB, p130 and p107) were 
assessed in wt-MCF7 and MCF7-LTEDY537C in the presence or absence of abiraterone (7.5 μM) 
after 48 hours treatment. (B) Time course assessment of cell cycle markers (CCND3, CDK4, 
pRB780, pRB807, RB) in MCF7-LTEDwt and MCF7-LTEDY537C in the presence of abiraterone 
(Abi) (7.5 μM) for 96 hours. (C) Quantification of PI-positive cells (wt-MCF7, MCF7-LTEDwt, 
MCF7-LTEDY537C, HCC1428-LTED) treated with escalating doses of abiraterone  for 6 days. 
Etoposide was used as a positive control (50μM). 
 
Supplementary Table S1. Ligand binding assay 
  
Figure S1. Effect of abiraterone on proliferation assessed in 3D spheroids. Images of 
HCC1428-LTED spheres in increasing concentrations of abiraterone accompanied with a 
viability assay of spheres. Bar equal 500 micrometres  
 
Figure S2. ER-mediated transactivation is increased in the presence of abiraterone in 
various AI-sensitive and AI-resistant ER+ breast cancer cell line models. (A) MCF7-
LTEDwt and MCF7-LTEDY537C were transfected with an ERE-luciferase (EREII-tk-luc) 
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reporter construct and treated with increasing doses of abiraterone. Data shown is 
representative of two biological experiments and three replicates per treatment. Bars represent 
± SEM. (B) Immunoblot assessment ER protein abundance after 48 hours treatment with 
escalating concentrations of abiraterone. (C) Cell lines (wt-HCC1428, HCC1428-LTED, wt-
SUM44 and SUM44-LTED) were transfected with an ERE-luciferase (EREII-tk-luc) reporter 
construct and treated with E2, abiraterone, ICI 182,780 (ICI) alone or in combination. Data is 
representative of two biological experiments with three replicates for each treatment. Bars 
represent ± SEM. 
 
Figure S3. Efficiency of the knock down in the wt-MCF7 and MCF7-LTEDY537C. (A) siER 
and (B) siAR. 
 
Figure S4 Impact of escalating concentrations of E2 on Cell viability. Wt-MCF7, wt-
SUM44, wt-HCC1428, MCF7-LTEDwt, SUM44-LTEDY537S, HCC1428-LTED were treated 
with increasing concentrations of E2 over 6 days. Cell viability was measured using TitreGlo 
and expressed as percent of viable cells relative to vehicle control. 
 
 
 
